Chiaojung Jillian Tsai, Lead of the Allan and Ruth Kerbel Palliative RT and Oligomet Program at Princess Margaret Cancer Centre, shared a post by OncoDaily Lung, adding:
“Thank you OncoDaily for highlighting the Canadian Cancer Trials Group BR.38/#CURB2 trial at American Society of Clinical Oncology (ASCO) 2026.
Note that this trial is sponsored by National Cancer Institute (NCI) and can be opened through:
- NRG ONCOLOGY (study champion Joseph Miccio)
- Alliance for Clinical Trials in Oncology (Meng Welliver)
- ECOG-ACRIN Cancer Research Group (John Varlotto)
- SWOG Cancer Research Network (Arya Amini).”
Quoting OncoDaily Lung‘s post:
“At the poster session, Chiaojung Jillian Tsai presented CCTG BR38/CURB2, a phase III study investigating the role of radiotherapy alongside continued systemic therapy in metastatic non-small cell lung cancer.”